勘误：接受生物制剂治疗的溃疡性结肠炎和克罗恩病儿科患者的临床结局评估：一项回顾性队列研究。
Erratum: Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn's Disease Receiving Biologics: A Retrospective Cohort Study.
出版信息
Crohns Colitis 360. 2022 Dec 9;4(4):otac049. doi: 10.1093/crocol/otac049. eCollection 2022 Oct.
Abstract
[This corrects the article DOI: 10.1093/crocol/otac009.].
摘要
[本文更正了文章的数字对象标识符：10.1093/crocol/otac009。]
相似文献
1
Erratum: Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn's Disease Receiving Biologics: A Retrospective Cohort Study.勘误：接受生物制剂治疗的溃疡性结肠炎和克罗恩病儿科患者的临床结局评估：一项回顾性队列研究。
Crohns Colitis 360. 2022 Dec 9;4(4):otac049. doi: 10.1093/crocol/otac049. eCollection 2022 Oct.
2
Correction to: Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.对《溃疡性结肠炎和克罗恩病中皮下注射维多珠单抗的实际应用场景实用入门指南：VISIBLE研究的事后分析》的勘误
Crohns Colitis 360. 2023 Nov 24;5(4):otad071. doi: 10.1093/crocol/otad071. eCollection 2023 Oct.
3
Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn's Disease Receiving Biologics: A Retrospective Cohort Study.接受生物制剂治疗的溃疡性结肠炎和克罗恩病儿科患者的临床结局评估：一项回顾性队列研究
Crohns Colitis 360. 2022 Mar 18;4(2):otac009. doi: 10.1093/crocol/otac009. eCollection 2022 Apr.
4
Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.肥胖对炎症性肠病疾病活动和结局的影响：来自瑞士炎症性肠病队列的研究结果。
United European Gastroenterol J. 2020 Dec;8(10):1196-1207. doi: 10.1177/2050640620954556.
5
Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease.血清基质金属蛋白酶-9 浓度作为炎症性肠病患者疾病活动的标志物。
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e803-e809. doi: 10.1097/MEG.0000000000002264.
6
A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis.一项基于人群的关于克罗恩病和溃疡性结肠炎儿科患者中皮质类固醇耐药和依赖频率的研究。
Inflamm Bowel Dis. 2006 Dec;12(12):1093-100. doi: 10.1097/01.mib.0000235835.32176.85.
7
8
Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.瑞士炎症性肠病相关住院前 12 个月治疗模式和医疗保健使用的系统分析。
Eur J Gastroenterol Hepatol. 2020 Mar;32(3):350-357. doi: 10.1097/MEG.0000000000001616.
9
Genetic determinants associated with early age of diagnosis of IBD.与炎症性肠病早期诊断相关的遗传决定因素。
Dis Colon Rectum. 2015 Mar;58(3):321-7. doi: 10.1097/DCR.0000000000000274.
10
Extraintestinal manifestation of inflammatory bowel disease and associated factors in pediatric patients.小儿炎症性肠病的肠外表现及相关因素
Ann Med Surg (Lond). 2022 Feb 15;75:103363. doi: 10.1016/j.amsu.2022.103363. eCollection 2022 Mar.
Zotero 插件